InterAx Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

InterAx Biotech is a private, preclinical-stage company leveraging a sophisticated systems biology platform to de-risk and accelerate GPCR drug discovery. Its core Deep Signal™ technology aims to translate a deep understanding of cellular signaling pathways into differentiated drug candidates with superior therapeutic profiles. With a seasoned leadership team and strong academic ties, particularly to the Paul Scherrer Institute and ETH Zürich, the company is positioned to address high-value targets in the GPCR space, a historically challenging but highly druggable family of proteins.

BiologicsSmall Molecules

Technology Platform

Deep Signal™ platform integrating mathematical modeling of cellular processes, experimental methods, and machine learning to decipher GPCR signaling and design novel drug candidates.

Opportunities

The large and growing market for GPCR-targeted therapies, coupled with high clinical failure rates, creates a major opportunity for a platform that can de-risk drug discovery.

InterAx's technology could enable lucrative partnerships with large pharma companies seeking to revitalize their GPCR pipelines or lead to the development of a valuable internal portfolio of novel, differentiated drug candidates.

Risk Factors

Key risks include the unproven predictive power of the complex Deep Signal™ platform in yielding successful clinical candidates, dependence on external funding as a pre-revenue company, and intense competition in the GPCR drug discovery space from both large pharma and other biotech platforms.

Competitive Landscape

InterAx competes with other biotechs applying computational and systems biology to drug discovery (e.g., Recursion, Insitro) and with large pharma internal efforts. Its specific focus on GPCR signaling depth is a differentiator, but it must prove its approach is superior in generating clinically successful outcomes.

More companies in Small Molecule Drugs →More companies in Switzerland →